Literature DB >> 28480678

Risk Factors for Recurrent Tuberculosis among Successfully Treated Patients in Israel, 1999-2011.

Valeria Zhdanov1, Natalya Bilenko1,2, Zohar Mor3,4.   

Abstract

BACKGROUND: Recurrent tuberculosis (TB) is one of the indices used to assess the effectiveness of the Israeli National TB Programs (NTP).
OBJECTIVES: To estimate the incidence of recurrent TB in Israel and to identify the associated risk factors.
METHODS: We conducted a retrospective cohort study of all TB patients who were Israeli citizens and diagnosed between 1999 and 2011 with a treatment outcome recorded as "success." We compared those who had recurrent TB with those who did not. In addition, a nested case-control study included all those who had recurrent TB with a random sample from this cohort matched by age, gender, and year of TB diagnosis.
RESULTS: Of 3515 TB patients diagnosed between 1999 and 2011, 37 (1.05%) had recurrent TB during the follow-up period, with an incidence rate of 1.55 cases per 1000 person-years (PY). Male gender [hazard ratio (HR) 3.2, 95% confidence interval (95%CI) 1.4-7.4], human immunodeficiency virus (HIV) infection (HR 3.9, 95%CI 1.5-10.4), positive sputum culture [odds ratios (OR) 2.7, 95%CI 1.1-6.9], and low adherence to anti-TB treatment (OR 3.2, 95%CI 1.0-10.3) were found to be risk factors for recurrent TB.
CONCLUSIONS: Male gender, HIV infection, positive sputum culture, and low adherence to anti-TB drugs during the initial TB episode were risk factors for developing recurrent TB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28480678

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  5 in total

1.  The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.

Authors:  L Mantshonyane; B Kgwaadira; R Gross
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 3.427

2.  IMPACT study on intervening with a manualised package to achieve treatment adherence in people with tuberculosis: protocol paper for a mixed-methods study, including a pilot randomised controlled trial.

Authors:  Helen R Stagg; Ibrahim Abubakar; Colin Nj Campbell; Andrew Copas; Marcia Darvell; Robert Horne; Karina Kielmann; Heinke Kunst; Mike Mandelbaum; Elisha Pickett; Alistair Story; Nicole Vidal; Fatima B Wurie; Marc Lipman
Journal:  BMJ Open       Date:  2019-12-17       Impact factor: 2.692

Review 3.  All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era.

Authors:  Helen R Stagg; Mary Flook; Antal Martinecz; Karina Kielmann; Pia Abel Zur Wiesch; Aaron S Karat; Marc C I Lipman; Derek J Sloan; Elizabeth F Walker; Katherine L Fielding
Journal:  ERJ Open Res       Date:  2020-11-02

4.  Predictors of recurrent TB in sputum smear and culture positive adults: a prospective cohort study.

Authors:  Grace Muzanyi; Y Mulumba; Paul Mubiri; Harriet Mayanja; John L Johnson; Ezekiel Mupere
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

5.  Temporal Factors and Missed Doses of Tuberculosis Treatment. A Causal Associations Approach to Analyses of Digital Adherence Data.

Authors:  Helen R Stagg; James J Lewis; Xiaoqiu Liu; Shitong Huan; Shiwen Jiang; Daniel P Chin; Katherine L Fielding
Journal:  Ann Am Thorac Soc       Date:  2020-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.